CN101180060B - 治疗或预防增殖性疾病的嘧啶基氨基苯甲酰胺化合物和伊马替尼的组合 - Google Patents

治疗或预防增殖性疾病的嘧啶基氨基苯甲酰胺化合物和伊马替尼的组合 Download PDF

Info

Publication number
CN101180060B
CN101180060B CN2006800181195A CN200680018119A CN101180060B CN 101180060 B CN101180060 B CN 101180060B CN 2006800181195 A CN2006800181195 A CN 2006800181195A CN 200680018119 A CN200680018119 A CN 200680018119A CN 101180060 B CN101180060 B CN 101180060B
Authority
CN
China
Prior art keywords
combination
acid
imatinib
lower alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800181195A
Other languages
English (en)
Chinese (zh)
Other versions
CN101180060A (zh
Inventor
L·埃兰德
P·W·曼雷
J·梅斯坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101180060A publication Critical patent/CN101180060A/zh
Application granted granted Critical
Publication of CN101180060B publication Critical patent/CN101180060B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2006800181195A 2005-06-03 2006-06-02 治疗或预防增殖性疾病的嘧啶基氨基苯甲酰胺化合物和伊马替尼的组合 Expired - Fee Related CN101180060B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68775805P 2005-06-03 2005-06-03
US60/687,758 2005-06-03
PCT/US2006/021307 WO2006132930A1 (en) 2005-06-03 2006-06-02 Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases

Publications (2)

Publication Number Publication Date
CN101180060A CN101180060A (zh) 2008-05-14
CN101180060B true CN101180060B (zh) 2011-12-28

Family

ID=36968749

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800181195A Expired - Fee Related CN101180060B (zh) 2005-06-03 2006-06-02 治疗或预防增殖性疾病的嘧啶基氨基苯甲酰胺化合物和伊马替尼的组合

Country Status (26)

Country Link
US (2) US7767688B2 (https=)
EP (1) EP1893213B1 (https=)
JP (2) JP5281887B2 (https=)
KR (1) KR101276425B1 (https=)
CN (1) CN101180060B (https=)
AT (1) ATE457727T1 (https=)
AU (1) AU2006255559B2 (https=)
BR (1) BRPI0611506A2 (https=)
CA (1) CA2608814C (https=)
CY (1) CY1110027T1 (https=)
DE (1) DE602006012313D1 (https=)
DK (1) DK1893213T3 (https=)
ES (1) ES2339593T3 (https=)
HR (1) HRP20100265T1 (https=)
IL (1) IL187408A0 (https=)
MA (1) MA29565B1 (https=)
MX (1) MX2007015159A (https=)
NO (1) NO20080037L (https=)
NZ (1) NZ563446A (https=)
PL (1) PL1893213T3 (https=)
PT (1) PT1893213E (https=)
RU (1) RU2430727C2 (https=)
SI (1) SI1893213T1 (https=)
TN (1) TNSN07453A1 (https=)
WO (1) WO2006132930A1 (https=)
ZA (1) ZA200709473B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006255559B2 (en) * 2005-06-03 2009-12-17 Novartis Ag Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
TW201102068A (en) * 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
CN102719530B (zh) * 2012-05-07 2013-11-06 厦门艾德生物医药科技有限公司 一种用于检测PDGFRα基因突变的引物、探针及试剂盒
KR101386697B1 (ko) * 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
AU2018306149B2 (en) 2017-07-26 2021-09-16 Ftf Pharma Private Limited Liquid dosage forms of imatinib
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1264375A (zh) * 1997-07-18 2000-08-23 诺瓦提斯公司 N－苯基－2－嘧啶胺衍生物的结晶变体,其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042042A1 (es) * 2002-11-15 2005-06-08 Sugen Inc Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
AU2006255559B2 (en) * 2005-06-03 2009-12-17 Novartis Ag Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1264375A (zh) * 1997-07-18 2000-08-23 诺瓦提斯公司 N－苯基－2－嘧啶胺衍生物的结晶变体,其制备方法和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
George D.efficacy and safety of imatinib mesylate in advancedgastrointestinal stromal tumors.the new england journal of medicine347 7.2002,347(7),472-480.
George D.efficacy and safety of imatinib mesylate in advancedgastrointestinal stromal tumors.the new england journal of medicine347 7.2002,347(7),472-480. *

Also Published As

Publication number Publication date
PL1893213T3 (pl) 2010-08-31
EP1893213A1 (en) 2008-03-05
RU2007147957A (ru) 2009-07-20
TNSN07453A1 (en) 2009-03-17
MA29565B1 (fr) 2008-06-02
CY1110027T1 (el) 2015-01-14
JP2013035853A (ja) 2013-02-21
MX2007015159A (es) 2008-02-15
ATE457727T1 (de) 2010-03-15
NZ563446A (en) 2011-02-25
US7767688B2 (en) 2010-08-03
AU2006255559B2 (en) 2009-12-17
IL187408A0 (en) 2011-07-31
DE602006012313D1 (de) 2010-04-01
EP1893213B1 (en) 2010-02-17
US8653093B2 (en) 2014-02-18
CN101180060A (zh) 2008-05-14
JP5281887B2 (ja) 2013-09-04
HRP20100265T1 (hr) 2010-06-30
KR20080021633A (ko) 2008-03-07
CA2608814C (en) 2013-09-03
SI1893213T1 (sl) 2010-05-31
KR101276425B1 (ko) 2013-06-19
ZA200709473B (en) 2008-12-31
US20100190800A1 (en) 2010-07-29
ES2339593T3 (es) 2010-05-21
DK1893213T3 (da) 2010-06-07
BRPI0611506A2 (pt) 2010-09-14
RU2430727C2 (ru) 2011-10-10
AU2006255559A1 (en) 2006-12-14
CA2608814A1 (en) 2006-12-14
US20080312252A1 (en) 2008-12-18
WO2006132930A1 (en) 2006-12-14
PT1893213E (pt) 2010-04-19
JP2008542390A (ja) 2008-11-27
NO20080037L (no) 2008-01-03
HK1115528A1 (en) 2008-12-05

Similar Documents

Publication Publication Date Title
US20080255171A1 (en) Combination of Nilotinib with Farnesyl Transferase Inhibitors
US8653093B2 (en) Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
JP2013127001A (ja) ピリミジルアミノベンズアミド化合物であるタンパク質キナーゼ阻害剤および１７−ａａｇのようなｈｓｐ９０阻害剤を含む組合せ剤
CA2647803C (en) Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
WO2007051862A1 (en) Combination of organic compounds
CN101160131A (zh) Bcr-abl和raf抑制剂的药物组合产品
AU2011202833B2 (en) Combination comprising a) a pyrimidylaminobenzamide compound, and b) a Thr315lle kinase inhibitor
CN101484172A (zh) 包含a)嘧啶基氨基苯甲酰胺化合物和b)thr315lle激酶抑制剂的组合
HK1115528B (en) Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20111228

Termination date: 20140602